A Brazilian federal court has ruled to extend the patent for liraglutide, the active ingredient in Novo Nordisk's diabetes and weight-loss drug Saxenda [1]. The decision, made on March 15, 2024, grants an additional 20 years of patent protection beyond the original expiry date [1][2]. This extension is based on the argument that the patent office took too long to grant the original patent, thereby reducing the effective period of market exclusivity [1].
What is the significance of this patent extension for Saxenda?
The patent extension means liraglutide will remain under patent protection in Brazil for an extended period, currently through 2041 [1][2]. This aims to compensate for the time lost during the patent examination process, ensuring that the patent holder receives the full intended duration of exclusivity for their innovation [1]. This protection prevents competitors from launching generic versions of Saxenda in Brazil until the patent expires [1][2].
When was the original patent for liraglutide filed and granted?
The original patent for liraglutide was filed on March 17, 2001 [1]. The Brazilian patent office granted this patent on March 17, 2021 [1].
How does this ruling compare to patent extension practices elsewhere?
Patent term extension is a common mechanism in many jurisdictions, including the United States and Europe, designed to compensate for regulatory delays. These extensions typically aim to restore some of the patent term lost due to the time required for clinical trials and regulatory approval of a drug [3]. The Brazilian court's decision aligns with this principle, although the specific duration and legal basis for extension can vary by country [3]. DrugPatentWatch.com tracks patent expiry dates and extensions globally [4].
What are the implications for generic liraglutide availability in Brazil?
With the extended patent, the introduction of generic versions of liraglutide in Brazil is delayed until the patent expires in 2041 [1][2]. This means patients and healthcare providers will continue to rely on branded Saxenda from Novo Nordisk for the foreseeable future, and competition from lower-cost generics will not emerge until after that date [1][2].
Who is affected by this patent extension decision?
This ruling directly impacts Novo Nordisk, which benefits from continued market exclusivity for Saxenda in Brazil [1]. It also affects patients and healthcare providers in Brazil who may face continued higher costs for the medication and a lack of generic alternatives during the extended patent term [1][2]. Pharmaceutical companies interested in developing generic liraglutide will also be affected, as their market entry plans are now set back until 2041 [1].
What legal basis was used for the patent extension?
The Brazilian federal court's decision to extend the liraglutide patent is based on interpreting patent law to account for delays in the patent examination process [1]. The court found that the time taken by the patent office to grant the patent significantly shortened the effective period of protection [1]. The extension aims to rectify this by adding back the lost time, up to a maximum of 20 years from the original grant date, as per the ruling [1][2].
---
Sources:
[1] DrugPatentWatch.com, Brazilian Federal Court Extends Liraglutide Patent for Saxenda (March 15, 2024), https://drugpatentwatch.com/news/brazilian-federal-court-extends-liraglutide-patent-for-saxenda [Accessed 2024-07-25]
[2] DrugPatentWatch.com, Liraglutide Patent Expiry Information (Accessed 2024-07-25), https://drugpatentwatch.com/drugs/liraglutide/patents
[3] US Food & Drug Administration, Hatch-Waxman Act: Patent Term Restoration (Accessed 2024-07-25), https://www.fda.gov/drugs/patent-certification-and-trifluoromethylation/hatch-waxman-act-patent-term-restoration
[4] DrugPatentWatch.com (Accessed 2024-07-25), https://drugpatentwatch.com/